Segment Information (Tables)

9 Months Ended

Sep. 30, 2014

Segment Information

Schedule of net revenues, cost of product sales and gross profit for each commercial product

Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

	Three Months Ended September 30,
2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
Net revenues	$	142,877	$	119,685	$	51,247	$	14,460	$	328,269
Cost of product sales	16,915		16,878		3,087		3,923		40,803
Gross profit	$	125,962	$	102,807	$	48,160	$	10,537	$	287,466
2013
Net revenues	$	132,322	$	120,306	$	47,378	$	—	$	300,006
Cost of product sales	13,549		14,245		2,922		—		30,716
Gross profit	$	118,773	$	106,061	$	44,456	$	—	$	269,290
	Nine Months Ended September 30,
2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
Net revenues	$	417,137	$	347,997	$	147,926	$	21,092	$	934,152
Cost of product sales	44,522		50,076		9,070		6,445		110,113
Gross profit	$	372,615	$	297,921	$	138,856	$	14,647	$	824,039
2013
Net revenues	$	371,314	$	324,409	$	124,924	$	—	$	820,647
Cost of product sales	40,439		44,125		7,785		—		92,349
Gross profit	$	330,875	$	280,284	$	117,139	$	—	$	728,298